Cytokinetics to Announce Fourth Quarter Results on February 27, 2025

Core Insights - Cytokinetics is scheduled to report its fourth quarter results on February 27, 2025, at 4:00 PM Eastern Time, followed by a conference call at 4:30 PM to discuss operational and financial results and future outlook [1][2] Company Overview - Cytokinetics is a late-stage biopharmaceutical company specializing in muscle biology, focused on developing drug candidates for diseases that compromise muscle performance [3] - The company is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial for obstructive hypertrophic cardiomyopathy (HCM) [3] - Cytokinetics is also developing omecamtiv mecarbil for heart failure with severely reduced ejection fraction (HFrEF), CK-586 for heart failure with preserved ejection fraction (HFpEF), and CK-089 for specific muscular dystrophies and impaired skeletal muscle function [3]